S. Grottoli et al., REDUCTION OF THE SOMATOTROPE RESPONSIVENESS TO GHRH AND HEXARELIN BUTNOT TO ARGININE PLUS GHRH IN HYPERPROLACTINEMIC PATIENTS, Journal of endocrinological investigation, 20(10), 1997, pp. 597-602
Aim of the present study was to verify the maximal secretory capacity
of somatotrope cells in patients with pathological hyperprolactinemia
(HPRL) comparing it with that in normal age-matched women (NW). To thi
s goal in 12 HPRL normal weight patients (age 28.6+/-2.6 yr, BMI 23.1/-1.1 kg/m(2)) and 8 NW (27.2+/-0.8 yr, 22.8+/-0.8 kg/m(2)) we studied
the GH response to GHRH (1 mu g/kg iv), GHRH plus arginine (ARG, 0.5
g/kg iv), an amino acid probably acting at the hypothalamic level inhi
biting somatostatin release, and Hexarelin (HEX, 2 mu g/kg iv), a synt
hetic hexapeptide belonging to GHRP family, which acts concomitantly a
t the pituitary and the hypothalamic level. IGF-I levels in HPRL were
similar to those in NW (179.2+/-16.5 mu g/l and 218.5+/-30.8 mu g/l).
In NW the GH response to GHRH (AUC: 1299.5+/-186.9 mu g.90 min/l) was
lower (p<0.02) than those to GHRH+ARG (5252.7+/-846.3 mu g.90 min/l) a
nd HEX (3216.6+/-462.3 mu g.90 min/l) which, in turn, were similar, In
HPRL the GH response to GHRH (894.7+/-242.4 mu g.90 min/l) was lower
(p<0.03) than that to HEX (1586.5+/-251.3 mu g.90 min/l) and both were
lower (p<0.03) than that to GHRH+ARG (4468.8+/-941.7 mu g.90 min/l).
In HPRL the GH responses to GHRH and HEX were lower than those that in
NW (p<0.03) while that to GHRH+ARG was similar in both groups, These
results demonstrate that the somatotrope responsiveness to GHRH and HE
X is clearly reduced in patients with pathological hyperprolactinemia.
On the other hand, in this condition the GH response to GHRH+ARG is n
ormal. As arginine likely acts via inhibition of hypothalamic somatost
atin release, these findings show that the maximal secretory capacity
of somatotrope cells in hyperprolactinemia is preserved and indicate t
hat partial refractoriness of somatotrope cells to GHRH and HEX could
be due to somatostatinergic hyperactivity. (C) 1997, Editrice Kurtis.